MedTrace Logo

Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome

NCT00666848 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-05-11

Study results available
· View outcomes & findings →

Summary

This study will measure the effect of the anti-diabetic agent sitagliptin on blood pressure in individuals with the metabolic syndrome. We will also measure the effect of sitagliptin on blood pressure in people already taking a blood pressure medication called an ACE inhibitor.

Conditions

Interventions

DRUG

Placebo

Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d

DRUG

Enalapril 5mg

Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d

DRUG

Enalapril 10mg

Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d

DRUG

Sitagliptin

Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Nancy J Brown, M.D. · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-08-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00666848 on ClinicalTrials.gov